Evidence map›Paper›PMID 35451598›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2022

Inhibition of p38 MAPK decreases hyperglycemia-induced nephrin endocytosis and attenuates albuminuria.

Magdalena Patrycja Woznowski, Sebastian Alexander Potthoff, Eva Königshausen, Raphael Haase, Henning Hoch, Catherine Meyer-Schwesinger, Thorsten Wiech, Johannes Stegbauer, Lars Christian Rump, Lorenz Sellin and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Magdalena Patrycja WoznowskiDepartment of Nephrology, Medical Faculty, Heinrich-Heine University, 40225, Düsseldorf, Germany. magdalena.woznowski@davita-dialyse.de.
Sebastian Alexander PotthoffDepartment of Nephrology, Medical Faculty, Heinrich-Heine University, 40225, Düsseldorf, Germany.ORCID 0000-0003-2568-8692
Eva KönigshausenDepartment of Nephrology, Medical Faculty, Heinrich-Heine University, 40225, Düsseldorf, Germany.
Raphael HaaseDepartment of Nephrology, Medical Faculty, Heinrich-Heine University, 40225, Düsseldorf, Germany.
Henning HochDepartment of Nephrology, Medical Faculty, Heinrich-Heine University, 40225, Düsseldorf, Germany.
Catherine Meyer-SchwesingerInstitute of Cellular and Integrative Physiology, University Clinic Hamburg-Eppendorf, 20246, Hamburg, Germany.
Thorsten WiechInstitute of Pathology, Nephropathology Section, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
Johannes StegbauerDepartment of Nephrology, Medical Faculty, Heinrich-Heine University, 40225, Düsseldorf, Germany.ORCID 0000-0001-8994-8102
Lars Christian RumpDepartment of Nephrology, Medical Faculty, Heinrich-Heine University, 40225, Düsseldorf, Germany.
Lorenz SellinDepartment of Nephrology, Medical Faculty, Heinrich-Heine University, 40225, Düsseldorf, Germany.
Ivo QuackEmergency Department, Klinikum Konstanz, 78464, Konstanz, Germany.
Heinrich Heine University Düsseldorf · DEUniversität Hamburg · DEKlinikum Konstanz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hyperglycemia, as in diabetes mellitus, may cause glomerular damage with microalbuminuria as an early sign. Noteworthy, even acute hyperglycemia can increase glomerular permeability before structural damage of the glomerular filter can be detected. Despite intensive research, specific antiproteinuric therapy is not available so far. Thus, a deeper understanding of the molecular mechanisms of albuminuria is desirable. P38 MAPK signaling is involved in the development of hyperglycemia-induced albuminuria. However, the mechanism of increased p38 MAPK activity leading to increased permeability and albuminuria remained unclear. Recently, we demonstrated that acute hyperglycemia triggers endocytosis of nephrin, the key molecule of the slit diaphragm, and induces albuminuria. Here, we identify p38 MAPK as a pivotal regulator of hyperglycemia-induced nephrin endocytosis. Activated p38 MAPK phosphorylates the nephrin c-terminus at serine 1146, facilitating the interaction of PKCα with nephrin. PKCα phosphorylates nephrin at threonine residues 1120 and 1125, mediating the binding of β-arrestin2 to nephrin. β-arrestin2 triggers endocytosis of nephrin by coupling it to the endocytic machinery, leading to increased glomerular permeability. Pharmacological inhibition of p38 MAPK preserves nephrin surface expression and significantly attenuates albuminuria. KEY MESSAGES: Acute hyperglycemia triggers endocytosis of nephrin. Activated p38 MAPK phosphorylates the nephrin c-terminus at serine 1146, facilitating the interaction of PKCα with nephrin. PKCα phosphorylates nephrin at threonine residues 1120 and 1125, mediating the binding of β-arrestin2 to nephrin. β-arrestin2 triggers endocytosis of nephrin by coupling it to the endocytic machinery, leading to a leaky glomerular filter. Pharmacological inhibition of p38 MAPK preserves nephrin surface expression and significantly attenuates albuminuria under hyperglycemic conditions.

Indexed as

AlbuminuriaHyperglycemiaMembrane Proteinsp38 Mitogen-Activated Protein KinasesPodocytesEndocytosisHumansProtein Kinase C-alphaSerineThreonineMembrane Proteinsnephrinp38 Mitogen-Activated Protein KinasesProtein Kinase C-alphaSerineThreonineAlbuminuriaDiabetesEndocytosisNephrinPodocyte

Identifiers

PMID35451598
PMCPMC9110524
OpenAlexW4224241851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.